These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 21577096

  • 1. Differential coagulation inhibitory effect of fondaparinux, enoxaparin and unfractionated heparin in cell models of thrombin generation.
    Ben-Hadj-Khalifa S, Hézard N, Almawi WY, Remy MG, Florent B, Mahjoub T, Nguyen P.
    Blood Coagul Fibrinolysis; 2011 Jul; 22(5):369-73. PubMed ID: 21577096
    [Abstract] [Full Text] [Related]

  • 2. Differential inhibitory effect of fondaparinux on the procoagulant potential of intact monocytes and monocyte-derived microparticles.
    Ben-Hadj-Khalifa-Kechiche S, Hezard N, Poitevin S, Remy MG, Florent B, Mahjoub T, Nguyen P.
    J Thromb Thrombolysis; 2010 Nov; 30(4):412-8. PubMed ID: 20602250
    [Abstract] [Full Text] [Related]

  • 3. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.
    Gerotziafas GT, Depasse F, Chakroun T, Van Dreden P, Samama MM, Elalamy I.
    Blood Coagul Fibrinolysis; 2004 Mar; 15(2):149-56. PubMed ID: 15091002
    [Abstract] [Full Text] [Related]

  • 4. Comparison of enoxaparin and unfractionated heparin on thrombin generation in acute coronary syndromes without ST-segment elevation.
    Salvioni A, Casilli F, Assanelli E, Grazi M, Marenzi G, Guazzi MD.
    Thromb Haemost; 2001 Oct; 86(4):991-4. PubMed ID: 11686357
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics and pharmacodynamics of a low molecular weight heparin (enoxaparin) after subcutaneous injection, comparison with unfractionated heparin--a three way cross over study in human volunteers.
    Bendetowicz AV, Béguin S, Caplain H, Hemker HC.
    Thromb Haemost; 1994 Mar; 71(3):305-13. PubMed ID: 8029794
    [Abstract] [Full Text] [Related]

  • 6. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L, Bal dit Sollier C, Martin J.
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [Abstract] [Full Text] [Related]

  • 7. Differential effects of direct thrombin inhibitors and antithrombin-dependent anticoagulants on the dynamics of clot formation.
    Young G, Yonekawa KE, Nakagawa PA, Blain RC, Lovejoy AE, Nugent DJ.
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):97-103. PubMed ID: 17287624
    [Abstract] [Full Text] [Related]

  • 8. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation.
    Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI.
    Thromb Res; 2002 Sep 01; 107(5):241-4. PubMed ID: 12479885
    [Abstract] [Full Text] [Related]

  • 9. Effects of unfractionated and low molecular weight heparins on plasma levels of hemostatic factors in patients with acute coronary syndromes.
    Vila V, Martínez-Sales V, Réganon E, Peris E, Perez F, Ruano M, Aznar J.
    Haematologica; 2001 Jul 01; 86(7):729-34. PubMed ID: 11454528
    [Abstract] [Full Text] [Related]

  • 10. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.
    Gatt A, van Veen JJ, Woolley AM, Kitchen S, Cooper P, Makris M.
    Thromb Haemost; 2008 Aug 01; 100(2):350-5. PubMed ID: 18690358
    [Abstract] [Full Text] [Related]

  • 11. Assay-Based Differentiation in the Neutralization Profile of Unfractionated Heparin, Enoxaparin, and Fondaparinux by Andexanet Alfa.
    Siddiqui F, Tafur A, Bontekoe E, Iqbal O, Jeske W, Mehrotra S, Hoppensteadt D, Ramacciotti E, Fareed J.
    Clin Appl Thromb Hemost; 2020 Aug 01; 26():1076029619895120. PubMed ID: 31914798
    [Abstract] [Full Text] [Related]

  • 12. Histones Differentially Modulate the Anticoagulant and Profibrinolytic Activities of Heparin, Heparin Derivatives, and Dabigatran.
    Ammollo CT, Semeraro N, Carratù MR, Colucci M, Semeraro F.
    J Pharmacol Exp Ther; 2016 Feb 01; 356(2):305-13. PubMed ID: 26578266
    [Abstract] [Full Text] [Related]

  • 13. Lack of clinically significant pharmacological interactions between ticagrelor and enoxaparin or unfractionated heparin in healthy subjects.
    Teng R, Butler K.
    J Clin Pharm Ther; 2012 Dec 01; 37(6):704-11. PubMed ID: 22747575
    [Abstract] [Full Text] [Related]

  • 14. The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma--a study in human volunteers.
    Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S.
    Thromb Haemost; 1994 Nov 01; 72(5):705-12. PubMed ID: 7900078
    [Abstract] [Full Text] [Related]

  • 15. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins.
    Wood JP, Baumann Kreuziger LM, Desai UR, Mast AE.
    Br J Haematol; 2016 Oct 01; 175(1):123-32. PubMed ID: 27301751
    [Abstract] [Full Text] [Related]

  • 16. High-dose tirofiban with enoxaparin and inflammatory markers in high-risk percutaneous intervention.
    Walters DL, Ray MJ, Wood P, Perrin EJ, Bett JH, Aroney CN.
    Eur J Clin Invest; 2010 Feb 01; 40(2):139-47. PubMed ID: 20039931
    [Abstract] [Full Text] [Related]

  • 17. Effects of fondaparinux compared with dalteparin, enoxaparin and unfractionated heparin on human osteoblasts.
    Matziolis G, Perka C, Disch A, Zippel H.
    Calcif Tissue Int; 2003 Oct 01; 73(4):370-9. PubMed ID: 12874702
    [Abstract] [Full Text] [Related]

  • 18. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile.
    Gerotziafas GT, Chakroun T, Samama MM, Elalamy I.
    Thromb Haemost; 2004 Dec 01; 92(6):1296-302. PubMed ID: 15583737
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic modulation of thrombin generation associated with human clots by human purified antithrombin alone or in the presence of low molecular weight heparin or unfractionated heparin.
    Meddahi S, Bara L, Fessi H, Samama MM.
    Blood Coagul Fibrinolysis; 2000 Jan 01; 11(1):51-9. PubMed ID: 10691099
    [Abstract] [Full Text] [Related]

  • 20. Routine use of fondaparinux in acute coronary syndromes: a 2-year multicenter experience.
    Schiele F, Meneveau N, Seronde MF, Descotes-Genon V, Dutheil J, Chopard R, Ecarnot F, Bassand JP, Reseau de Cardiologie de Franche Comte.
    Am Heart J; 2010 Feb 01; 159(2):190-8. PubMed ID: 20152216
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.